Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | QDPR | P09417 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2317377 | 0.83 | EPHX2 (0.44) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL4496703 | 0.77 | — | — | |
| SCHEMBL2320236 | 0.75 | CYP4F2 (0.42) | EPHX2EPHX1 | |
| SCHEMBL15568164 | 0.73 | ALOX5 (0.31) | EPHX1CYP1A2TDP1 | |
| SCHEMBL14167712 | 0.73 | GPR119 (0.44) | — | |
| SCHEMBL29191211 | 0.72 | HPGD (0.43) | EPHX1KDM4ESMN1; SMN2 | |
| SCHEMBL27778461 | 0.71 | EPHX2 (0.42) | EPHX2EPHX1 | |
| SCHEMBL27799384 | 0.71 | EPHX2 (0.42) | EPHX2EPHX1 | |
| SCHEMBL994460 | 0.71 | EPHX1 (0.38) | EPHX2EPHX1CYP1A2TDP1KDM4E | |
| SCHEMBL8215631 | 0.70 | EPHX2 (0.43) | EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2928868-B1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2017-08-09 | — | — | EP | claimed |
| US-9303012-B2 | Pyridine-2-amides useful as CB2 agonists | HOFFMAN-LA ROCHE INC. (US) | 2016-04-05 | — | — | US | claimed |
| US-20150299165-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-22 | — | — | US | claimed |
| EP-2928868-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-10-14 | — | — | EP | claimed |
| WO-2014086806-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | claimed |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2010-04-29 | — | — | US | claimed |
| EP-2041141-A2 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2009-04-01 | — | — | EP | claimed |
| WO-2008006883-A2 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2008-01-17 | — | — | WO | claimed |
| EP-2928868-B1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2017-08-09 | — | — | EP | disclosed |
| US-9303012-B2 | Pyridine-2-amides useful as CB2 agonists | HOFFMAN-LA ROCHE INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150299165-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-22 | — | — | US | disclosed |
| EP-2928868-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014086806-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-12 | — | — | WO | disclosed |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2010-04-29 | — | — | US | disclosed |
| EP-2041141-A2 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008006883-A2 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299165-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | CNR2, CNR1, GPR52 | EPHX2 727/4885EPHX1 903/4885CYP1A2 315/4885 |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | BAX, BCL2, BAD | EPHX2 4100/4885EPHX1 3284/4885CYP1A2 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.